cmAngio® V2.0
Curemetrix, Inc. · K260980
FDA-authorized Predetermined Change Control Plan
- Company
- Curemetrix, Inc.
- 510(k)/De Novo #
- K260980
- Decision date
- 2026-07-30
- Panel
- Radiology
- Pathway
- 510(k)
- Category
- AI/SaMD
- PCCP type
- Unknown
- Monitoring commitment
- Unknown
Other Radiology PCCPs
- K261210Cleerly PlaqueCleerly, Inc.2026-07-29AI/SaMDRetraining
- K253770CardIQ SuiteGE Medical Systems SCS2026-07-21AI/SaMDRetraining
- K261085Rapid Vessel Occlusion (Rapid VO)iSchemaview2026-07-13AI/SaMDRetraining
- K260973InferOperate SuiteBeijing Infervision Healthcare Medical Technology Co., Ltd.2026-07-07AI/SaMDRetraining
- K253884Koios DS (3.8)Koios Medical, Inc.2026-07-02AI/SaMDRetraining
- K260714MammoScreen® (5)Therapixel2026-06-26AI/SaMDCompatibility expansion
Want the monitoring teardown?
We read the PCCP for cmAngio® V2.0, then map the post-market monitoring that its modification protocol requires, including the deployment-period evidence most teams can't reconstruct at modification time. Sentir is the independent system of record that produces it.
Book a callSource: U.S. FDA public records (openFDA 510(k)/De Novo databases and accessdata.fda.gov). PCCP type and category are editorial classifications based on public documents, not official FDA designations.
This page is a factual summary of public FDA records. Sentir Health is not affiliated with or endorsed by the named companies or the U.S. Food and Drug Administration. Spot an error? Request a correction.